ferric-ammonium-citrate and Osteoarthritis

ferric-ammonium-citrate has been researched along with Osteoarthritis* in 1 studies

Other Studies

1 other study(ies) available for ferric-ammonium-citrate and Osteoarthritis

ArticleYear
Calcium chelator BAPTA‑AM protects against iron overload‑induced chondrocyte mitochondrial dysfunction and cartilage degeneration.
    International journal of molecular medicine, 2021, Volume: 48, Issue:4

    Osteoarthritis (OA) is a common joint disease that is characterized by cartilage degradation. Iron deposition in the joints is common during the pathogenic progression of OA and recent studies have indicated that iron overload is an important contributor to OA progression. Calcium chelators have been reported to inhibit iron influx via modulating transferrin receptor protein 1 internalization, and they have been identified as a potential approach to the treatment of iron overload‑induced diseases. The aim of the present study was to investigate the effect of calcium chelators on the progression of iron overload‑induced OA. Primary chondrocytes were treated with various concentrations of ferric ammonium citrate (FAC) to mimic iron overload

    Topics: Animals; Apoptosis; Calcium Chelating Agents; Cartilage Diseases; Cartilage, Articular; Cell Survival; Cells, Cultured; Chondrocytes; Egtazic Acid; Ferric Compounds; Iron Overload; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Diseases; Osteoarthritis; Protective Agents; Quaternary Ammonium Compounds; Reactive Oxygen Species

2021